CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab

J. J. Ifthikharuddin, L. A. Mieles, J. D. Rosenblatt, C. K. Ryan, D. M. Sahasrabudhe

Research output: Contribution to journalArticle

33 Scopus citations


B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)171-173
Number of pages3
JournalAmerican Journal of Hematology
Issue number2
StatePublished - Oct 5 2000
Externally publishedYes



  • CD-20
  • Post-transplant lymphoproliferative disorder
  • PTLD
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this